These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 26596901)
1. Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4. Allen BK; Mehta S; Ember SW; Schonbrunn E; Ayad N; Schürer SC Sci Rep; 2015 Nov; 5():16924. PubMed ID: 26596901 [TBL] [Abstract][Full Text] [Related]
2. In silico study directed towards identification of novel high-affinity inhibitors targeting an oncogenic protein: BRD4-BD1. Tumdam R; Kumar A; Subbarao N; Balaji BS SAR QSAR Environ Res; 2018 Dec; 29(12):975-996. PubMed ID: 30411639 [TBL] [Abstract][Full Text] [Related]
3. BET Bromodomain as a Target of Epigenetic Therapy. Noguchi-Yachide T Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788 [TBL] [Abstract][Full Text] [Related]
4. Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains. Wang J; Erazo T; Ferguson FM; Buckley DL; Gomez N; Muñoz-Guardiola P; Diéguez-Martínez N; Deng X; Hao M; Massefski W; Fedorov O; Offei-Addo NK; Park PM; Dai L; DiBona A; Becht K; Kim ND; McKeown MR; Roberts JM; Zhang J; Sim T; Alessi DR; Bradner JE; Lizcano JM; Blacklow SC; Qi J; Xu X; Gray NS ACS Chem Biol; 2018 Sep; 13(9):2438-2448. PubMed ID: 30102854 [TBL] [Abstract][Full Text] [Related]
5. Investigation of novel ligand targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery: complete pharmacophore approach. Shanmugam V; Muthukrishnan S J Biomol Struct Dyn; 2023; 41(23):14524-14539. PubMed ID: 36841551 [TBL] [Abstract][Full Text] [Related]
6. Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation. Xue X; Zhang Y; Liu Z; Song M; Xing Y; Xiang Q; Wang Z; Tu Z; Zhou Y; Ding K; Xu Y J Med Chem; 2016 Feb; 59(4):1565-79. PubMed ID: 26731490 [TBL] [Abstract][Full Text] [Related]
7. Machine-Learning-Assisted Approach for Discovering Novel Inhibitors Targeting Bromodomain-Containing Protein 4. Xing J; Lu W; Liu R; Wang Y; Xie Y; Zhang H; Shi Z; Jiang H; Liu YC; Chen K; Jiang H; Luo C; Zheng M J Chem Inf Model; 2017 Jul; 57(7):1677-1690. PubMed ID: 28636361 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery. Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938 [TBL] [Abstract][Full Text] [Related]
9. Discovery of a Small-Molecule Bromodomain-Containing Protein 4 (BRD4) Inhibitor That Induces AMP-Activated Protein Kinase-Modulated Autophagy-Associated Cell Death in Breast Cancer. Ouyang L; Zhang L; Liu J; Fu L; Yao D; Zhao Y; Zhang S; Wang G; He G; Liu B J Med Chem; 2017 Dec; 60(24):9990-10012. PubMed ID: 29172540 [TBL] [Abstract][Full Text] [Related]
10. Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis. Andrews FH; Singh AR; Joshi S; Smith CA; Morales GA; Garlich JR; Durden DL; Kutateladze TG Proc Natl Acad Sci U S A; 2017 Feb; 114(7):E1072-E1080. PubMed ID: 28137841 [No Abstract] [Full Text] [Related]
11. Small-Molecule Targeting of BET Proteins in Cancer. French CA Adv Cancer Res; 2016; 131():21-58. PubMed ID: 27451123 [TBL] [Abstract][Full Text] [Related]
12. Targeting BET bromodomains for cancer treatment. Jung M; Gelato KA; Fernández-Montalván A; Siegel S; Haendler B Epigenomics; 2015; 7(3):487-501. PubMed ID: 26077433 [TBL] [Abstract][Full Text] [Related]
13. Discovery of novel BRD4 inhibitors by high-throughput screening, crystallography, and cell-based assays. Sun Z; Zhang H; Chen Z; Xie Y; Jiang H; Chen L; Ding H; Zhang Y; Jiang H; Zheng M; Luo C Bioorg Med Chem Lett; 2017 May; 27(9):2003-2009. PubMed ID: 28347667 [TBL] [Abstract][Full Text] [Related]
14. Importance of a crystalline water network in docking-based virtual screening: a case study of BRD4. Zhong H; Wang Z; Wang X; Liu H; Li D; Liu H; Yao X; Hou T Phys Chem Chem Phys; 2019 Dec; 21(45):25276-25289. PubMed ID: 31701109 [TBL] [Abstract][Full Text] [Related]
15. Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors. Ember SW; Zhu JY; Olesen SH; Martin MP; Becker A; Berndt N; Georg GI; Schönbrunn E ACS Chem Biol; 2014 May; 9(5):1160-71. PubMed ID: 24568369 [TBL] [Abstract][Full Text] [Related]
16. Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy. Stratikopoulos EE; Dendy M; Szabolcs M; Khaykin AJ; Lefebvre C; Zhou MM; Parsons R Cancer Cell; 2015 Jun; 27(6):837-51. PubMed ID: 26058079 [TBL] [Abstract][Full Text] [Related]
17. Molecular docking and dynamics simulation study of flavonoids as BET bromodomain inhibitors. Raj U; Kumar H; Varadwaj PK J Biomol Struct Dyn; 2017 Aug; 35(11):2351-2362. PubMed ID: 27494802 [TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of dihydroquinoxalinone derivatives as BRD4 inhibitors. Yang Y; Zhao L; Xu B; Yang L; Zhang J; Zhang H; Zhou J Bioorg Chem; 2016 Oct; 68():236-44. PubMed ID: 27580186 [TBL] [Abstract][Full Text] [Related]
20. Discovery of novel [1,2,4]triazolo[4,3-a]quinoxaline aminophenyl derivatives as BET inhibitors for cancer treatment. Ali I; Lee J; Go A; Choi G; Lee K Bioorg Med Chem Lett; 2017 Oct; 27(20):4606-4613. PubMed ID: 28939121 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]